Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis

View ORCID ProfileJineta Banerjee, View ORCID ProfileJan M. Friedman, View ORCID ProfileLaura J. Klesse, View ORCID ProfileKaleb Yohay, Children’s Tumor Foundation Clinical Care Advisory Board, Justin T Jordan, View ORCID ProfileScott Plotkin, View ORCID ProfileRobert J Allaway, View ORCID ProfileJaishri Blakeley
doi: https://doi.org/10.1101/2022.03.31.22273208
Jineta Banerjee
1Sage Bionetworks, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jineta Banerjee
Jan M. Friedman
2Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jan M. Friedman
Laura J. Klesse
3Department of Pediatrics and Neurosurgery, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura J. Klesse
Kaleb Yohay
4Comprehensive Neurofibromatosis Center at NYU Langone Health, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kaleb Yohay
Justin T Jordan
5Department of Neurology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Plotkin
6Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Scott Plotkin
Robert J Allaway
1Sage Bionetworks, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert J Allaway
Jaishri Blakeley
7Departments of Neurology, Oncology, and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jaishri Blakeley
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Purpose People with pre-existing conditions may be more susceptible to severe Coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The relative risk and severity of SARS-CoV-2 infection in people with rare diseases like neurofibromatosis (NF) type 1 (NF1), neurofibromatosis type 2 (NF2), or schwannomatosis (SWN) is unknown.

Methods We investigated the proportions of SARS-CoV-2 positive or COVID-19 patients in people with NF1, NF2, or SWN in the National COVID Collaborative Cohort (N3C) electronic health record dataset.

Results The cohort sizes in N3C were 2,501 (NF1), 665 (NF2), and 762 (SWN). We compared these to N3C cohorts of other rare disease patients (98 - 9844 individuals) and the general non-NF population of 5.6 million. The site- and age-adjusted proportion of people with NF1, NF2, or SWN who tested positive for SARS-CoV-2 or were COVID-19 patients (collectively termed positive cases) was not significantly higher than in individuals without NF or other selected rare diseases. There were no severe outcomes reported in the NF2 or SWN cohorts. The proportion of patients experiencing severe outcomes was no greater for people with NF1 than in cohorts with other rare diseases or the general population.

Conclusion Having NF1, NF2, or SWN does not appear to increase the risk of being SARS-CoV-2 positive or of being a COVID-19 patient, or of developing severe complications from SARS-CoV-2.

Competing Interest Statement

Justin T Jordan is a recipient of royalties from Elsevier, and consulting fees from Navio Theragnostics, CereXis, and Recursion Inc. Scott Plotkin is co-founder of NFlection Therapeutics, NF2 Therapeutics; consults for Akouos; and serves on the Scientific Advisory Board and holds stock in SonALAsense.

Funding Statement

This study was funded by the Neurofibromatosis Therapeutic Acceleration Program, and supported by the Clinical Care Advisory Board of Children's Tumor Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Western Institutional Review Board - Copernicus Group (WCG) IRB of Sage Bionetworks gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data analyzed in this study are available online at the N3C Data Enclave (https://covid.cd2h.org/enclave). Access to data requires approval from the N3C data access committee. No new data was produced in this study. All the R code used for the analyses in this study is available on Github (https://github.com/jaybee84/NF-COVID-response).

https://covid.cd2h.org/enclave

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
Jineta Banerjee, Jan M. Friedman, Laura J. Klesse, Kaleb Yohay, Children’s Tumor Foundation Clinical Care Advisory Board, Justin T Jordan, Scott Plotkin, Robert J Allaway, Jaishri Blakeley
medRxiv 2022.03.31.22273208; doi: https://doi.org/10.1101/2022.03.31.22273208
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
Jineta Banerjee, Jan M. Friedman, Laura J. Klesse, Kaleb Yohay, Children’s Tumor Foundation Clinical Care Advisory Board, Justin T Jordan, Scott Plotkin, Robert J Allaway, Jaishri Blakeley
medRxiv 2022.03.31.22273208; doi: https://doi.org/10.1101/2022.03.31.22273208

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3292)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13374)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14627)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1705)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)